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Abstract
DNA methylation is a key epigenetic modification which, in mammals, occurs mainly at CpG dinucleotides. Most of the CpG
methylation in the genome is found in repetitive regions, rich in dormant transposons and endogenous retroviruses. Global
DNA hypomethylation, which is a common feature of several conditions such as ageing and cancer, can cause the
undesirable activation of dormant repeat elements and lead to altered expression of associated genes. DNA
hypomethylation can cause genomic instability and may contribute to mutations and chromosomal recombinations.
Various approaches for quantification of global DNA methylation are widely used. Several of these approaches measure a
surrogate for total genomic methyl cytosine and there is uncertainty about the comparability of these methods. Here we
have applied 3 different approaches (luminometric methylation assay, pyrosequencing of the methylation status of the Alu
repeat element and of the LINE1 repeat element) for estimating global DNA methylation in the same human cell and tissue
samples and have compared these estimates with the ‘‘gold standard’’ of methyl cytosine quantification by HPLC. Next to
HPLC, the LINE1 approach shows the smallest variation between samples, followed by Alu. Pearson correlations and Bland-
Altman analyses confirmed that global DNA methylation estimates obtained via the LINE1 approach corresponded best
with HPLC-based measurements. Although, we did not find compelling evidence that the gold standard measurement by
HPLC could be substituted with confidence by any of the surrogate assays for detecting global DNA methylation
investigated here, the LINE1 assay seems likely to be an acceptable surrogate in many cases.
Citation: Lisanti S, Omar WAW, Tomaszewski B, De Prins S, Jacobs G, et al. (2013) Comparison of Methods for Quantification of Global DNA Methylation in Human
Cells and Tissues. PLoS ONE 8(11): e79044. doi:10.1371/journal.pone.0079044
Editor: Keith William Brown, University of Bristol, United Kingdom
Received July 12, 2013; Accepted September 26, 2013; Published November 18, 2013
Copyright:  2013 Lisanti et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits
unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Funding: This research was supported by the BBSRC and EPSRC through the Centre for Integrated Systems Biology of Ageing and Nutrition (CISBAN) (BB/
C008200/1) and by the Centre for Brain Ageing & Vitality, which is funded under the Lifelong Health and Wellbeing cross council initiative by the MRC, BBSRC,
EPSRC and ESRC. Wan A.W. Omar was supported by the Advance Medical and Dental Institute, Universiti Sains Malaysia, Malaysia. The funders had no role in study
design, data collection and analysis, decision to publish, or preparation of the manuscript.
Competing Interests: The authors have declared that no competing interests exist.
* E-mail: sabine.langie@gmail.com
. These authors contributed equally to this work.
Introduction
DNA methylation is a chemical modification of the genome
which involves the covalent addition of a methyl group to DNA,
mainly occurring at cytosine residues within CpG dinucleotides.
Although in mammalian genomes the CpG dinucleotide is under-
represented, unusually dense clusters of CpG dinucleotides called
‘‘CpG islands’’ are present [1] and overlap promoter regions of
50%–60% of human genes [2], thus suggesting that DNA
methylation plays a role in the regulation of gene expression.
Nonetheless most of the DNA methylation in mammalian
genomes is found in repetitive elements, such as transposons and
endogenous retroviruses [3]. Transposable elements, which
include long terminal repeats (LTR)-retrotransposons, long and
short interspersed nuclear elements (LINE and SINE, respectively)
and DNA transposons constitute about 45% of the human
genome. These sequences could interfere with the regulation of
gene expression and genome structure by means of insertions,
deletions, inversions and translocations of genomic sequences.
However, this potential damage is decreased by high levels of CpG
methylation which effectively silences these repetitive regions [3,4].
Altered global DNA methylation content is a feature of several
diseases; its occurrence in human tumors was first highlighted by
Gama-Sosa et al. [5]. Hypermethylation of the promoter regions
of tumor suppressor genes and DNA repair genes, such as MLH1,
causes gene silencing and contributes causally to tumorigenesis [6].
Similar gene silencing effects are seen in Fragile X Syndrome
[7,8]. Altered patterns of DNA methylation are observed during
ageing, some of which correlate with age-related frailty and other
age-dependent phenotypes [9–11]. Recent studies have identified
cancer-specific differentially DNA-methylated regions in colon
cancer [12] and other solid tumors including lung, breast, thyroid
and Wilms’ tumors [13]. These cancer-specific changes include
hypomethylation of approximately 50% of the genome which was
associated with high levels of variability in gene expression [13].
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Several approaches have been developed which are regarded as
gold standard methods for measurement of global methylation
(e.g. high performance liquid chromatography (HPLC) [14] or
variants of this approach such as HPLC tandem mass spectrom-
etry (LC-MS/MS) [15], as well as two dimensional thin layer
chromatography [16] and high performance capillary electropho-
resis [17]). After DNA digestion, in chromatographic approaches
e.g. HPLC, the single nucleotides are separated according to size
and both cytosine and methylated cytosine are quantified [14].
Whilst this method is highly quantitative and reproducible, it
requires relatively large amounts of DNA and the protocol for
assay optimization is demanding. Thus other methods to estimate
global methylation content that require less DNA and use more
readily available equipment have been developed. These include
PCR based methods which estimate the methylation status of
major genomic repeat elements e.g. Alu and LINE1 [18] and
methylation sensitive restriction assays such as the luminometric
methylation assay (LUMA) [19,20].
In the Alu and LINE1 assays, the methylation status of specific
cytosine residues in bisulfite converted DNA is quantified, often by
pyrosequencing. Since bisulfite treatment converts non-methylated
cytosines to uracil residues that are converted to thymidine in a
subsequent PCR reaction, the ratio of cytosine/converted
thymidine residues is indicative of the methylation status of the
sequence of interest. In the LUMA assay, DNA samples are
digested in parallel with the isoschizomers MspI (unaffected by
methylation) and HpaII (methylation sensitive), which recognize
the same sequence (CCGG), and cut differentially according to the
methylation state of the internal cytosine residue. The digestion
ratio HpaII/MspI can be determined by pyrosequencing and the
resulting ratio is inversely proportional to the methylation content
of the sample.
Compared with HPLC, these methods may be less expensive
and require less starting material, but they provide information on
methylation levels limited to the specific analyzed sequences.
Although these simplified approaches for global DNA methylation
estimation are widely used as surrogates for total genomic DNA
methylation, there is uncertainty about their comparability and the
extent to which they reflect measurements of total methyl cytosine
content of DNA.
In this paper, we applied three surrogate approaches (Alu,
LINE1 and LUMA) for global DNA methylation estimation to the
assay of a range of human cells and tissues, namely: HeLa cells
(human cervical cancer cells) and M059J cells (human glioblasto-
ma cancer cells) both untreated and treated with the demethyl-
ating agent 5-azacytidine, and human colon biopsies (matched
normal mucosa and tumor tissue from the same patients). Our
criteria for utility of individual approaches for estimating global
DNA methylation included: i) ability to detect biologically
important differences in tissue methylation (tumor vs. normal), ii)
ability to detect effects of a demethylating agent (5-azacytidine), iii)
concordance of results using each approach with data obtained by
the gold standard assay (HPLC) and iv) variability of results, ease
of use and relative costs.
Materials and Methods
Human colonic biopsies
Colon biopsies were collected from patients (n = 10) who
underwent surgery for colorectal cancer at Wansbeck General
Hospital (Ashington, Northumberland, UK). All of these patients
gave written informed consent. Ethical approval was received from
the Northumberland Local Research Ethics Committee (project
reference NLREC2/2001). Samples of both normal mucosa
(.10 cm from tumor margin) and matched tumor tissue from
the same patient were collected in the operating theatre,
immediately after tissue resection. All samples were snap-frozen
immediately in liquid nitrogen and stored at280uC. Details of this
study have been published [21].
Cell culture and 5-azacytidine (5-AzaC) treatment
HeLa and M059J cells were cultured in DMEM (Sigma)
supplemented with 10% heat inactivated FCS and 1% penicillin/
streptomycin. Cells were maintained at 37uC in a 5% CO2
atmosphere. To generate cells with different levels of DNA
methylation, cells at approximately 50% confluency were treated
with 5 mM of the demethylating agent 5-azacytidine (5-AzaC,
Sigma). Treatment continued for 3 days, while replacing DMEM
plus 5-AzaC daily. After treatment, cells were harvested, divided in
3 aliquots and frozen as cell pellets at 280uC.
Various assays to measure global DNA methylation
Table 1 provides an overview of each of the individual
approaches used in this study for estimating global DNA
methylation, along with the biological relevance of the variable
measured. Further details of these assays are given below.
Estimation of LINE1 and Alu methylation using
pyrosequencing of bisulfite converted DNA. Cells and
colonic biopsies were assayed for global DNA methylation using
the LINE1 assay described by Bollati et al. [22]. For Alu, the site
of interest was the region described by Chen et al. [23], which
Table 1. Overview of various assays to assess global DNA methylation, depicting their biological relevance.
Assay Biological relevance
Amount of DNA required
(used in our assay) Equipment needed
LINE1 ,700,00 copies, which relates to ,17% in
human genome1
500 pg –2 mg (250 ng) Thermal cycler, Pyrosequencer
Alu ,1,100,00 copies, which relates to ,11% in
human genome1
500 pg –2 mg (250 ng) Thermal cycler, Pyrosequencer
LUMA Proportion of CpGs located within HpaII
sites (5‘CCGG’3) in the human
genome is 4.14% in transposable elements +3.90%
in unique sequence (8.04% in total)#
100 2500 ng (100 ng) Incubator, Pyrosequencer
HPLC-UV Total 5mC in the human genome 1 –5mg (3 mg) HPLC
1Information taken from [37] and [38]. # Information taken from [39].
doi:10.1371/journal.pone.0079044.t001
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contains an Alu repetitive element. Each sample was assayed in
duplicate.
DNA was extracted from cells and tissues using standard
chloroform: isoamyl alcohol extraction. Bisulfite conversion of
DNA was performed using EZ DNA Methylation GoldTM kit
(Zymo Research) according to the manufacturer’s protocol. Briey,
250 ng of genomic DNA was incubated with CT conversion
reagent at the following temperatures: 98uC for 10 min, 64uC for
2.5 hours, held at 4uC. Subsequently, DNA was transferred to a
spin column, washed, desulphonated, further purified using
columns, and finally eluted in a volume of 10 ml.
One microliter of bisulfite-treated DNA was added as a
template in a PCR reaction containing 12.5 mL Hot Star Taq
mastermix (Qiagen), 400 nM forward primer and 400 nM Biotin-
labelled reverse primer in a total volume of 25 mL. The primer
sequences and PCR conditions are summarized in Table 2.
Amplification was carried out in a G-storm thermocycler (GRI
Ltd) using the following protocol; 95uC 15 min, then 50 cycles of
95uC 15 s, annealing temperature for 30 s (55uC for LINE1 and
47uC for Alu), 72uC for 15 s, followed by 72uC for 5 min.
Biotin-labelled PCR products were captured with Streptavidin
Sepharose beads (GE Healthcare), and made single stranded using
a Pyrosequencing Vacuum Prep Tool (Qiagen). The appropriate
sequencing primer (Table 2) was annealed to the single-stranded
PCR product by heating to 80uC, followed by slow cooling.
Pyrosequencing was carried out on a Pyromark MD system
(Qiagen) and cytosine methylation was quantified using Pyro Q
CpG 1.0.6 software.
Modified LUMA assay. The luminometric methylation
assay (LUMA) was performed as described by Karimi et al.
[20], with some modifications. We observed ‘‘star activity’’ when
using the enzyme EcoRI as normalizer and therefore modified the
assay using MunI as a normalization reference (Figure S1).
Although, star activity of EcoRI could be prevented by using 2x
Tango buffer (Figure S1B), MspI and HpaII are reported to have
reduced activity in this buffer (see analysis certificates on
Fermentas Life Sciences website). Moreover, methylation of
CpG dinucleotides in the EcoRI restriction site impairs its
cleavage activity (Figure S1E). MunI has similar cutting sites
(Table 3) but exhibits better enzymatic activities when compared
with EcoR1 and we observed complete DNA digestion without
unspecific cuts with MunI compared with EcoRI.
After optimizing the protocol with MunI as normalizer (see
validation curves and digestion pattern in Figure S1), we
performed the following steps for all experiments. Briefly,
100 ng genomic DNA was digested in 2 separate 35 mL reactions
with MunI/MspI or MunI/HpaII (final concentration 2.5 U/mL
each; New England Biolabs) in 1x Tango Buffer (Frementas) for
16 h at 37uC. When digestion was complete, 35 mL annealing
buffer (Qiagen) was added to each digestion tube. Next, the digests
were distributed in triplicates (3620 mL) in a 96-well PCR plate for
analysis by pyrosequencing (PyroMark MD, Biotage). Global
genome methylation (%) was calculated as follows;
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x100
with C= Peak height ‘C’ results, and A= Peak height ‘A’ results.
Determination of 5-methylcytosine by HPLC. Frozen
tissues or cell pellets were thawed and genomic DNA was isolated
using standard chloroform: iso-amyl alcohol extraction. The
genomic content of the nucleoside 5-methyl-29-deoxycytidine
was quantified by HPLC with UV detection. DNA digestion was
performed as described by Rozhon et al. (Rozhon et al., 2008). In
short, DNA was incubated overnight at 37uC with a mixture of
Dnase I and nuclease P1 (both enzymes from Sigma-Aldrich, St.
Louis, MO, USA). Next, nucleotide monophosphates were
dephosphorylated for a further 24 h at 37uC with calf intestine
alkaline phosphatase (New England Biolabs, Ipswich, MA, USA).
29-deoxycytidine (dC) and 5-methyl-29-deoxycytidine (5mdC)
concentrations were measured with an Acquity Ultra Performance
Liquid Chromatography (UPLC) system (Waters, Milford, MA,
USA) which was used in high performance LC (HPLC) mode. The
HPLC protocol consisted of isocratic separation using a Nucleosil
SA cation exchange silica 15064.6 mm x5 mm column (Ma-
cherey-Nagel, Du¨ren, Germany) at a temperature of 30uC. The
acidic mobile phase consisted of 50 mM ammonium acetate in
15% acetonitrile with a pH of 4.8. The flow rate was set at
0.5 mL/min and the injected sample volume was 30 mL. Samples
were cooled at 4uC. UV detection was performed at 272 nm for
dC and at 279 nm for 5mdC. The retention times for dC and
5mdC were 6 min 12 s and 7 min 16 s respectively. Chromato-
grams were analyzed using Empower 2 software (Waters). Levels
of 5mdC and dC were estimated based on the corresponding
standard curve which ranged from 2 to 0.008 mg/mL for 5mdC
and from 20 to 0.08 mg/mL for dC (both standards from MP
Biochemicals, Santa Ana, CA, USA). The relative content of
5mdC was expressed as a percentage (%5mdC) with respect to the
total amount of cytosine (dC +5mdC). The technical variation of
this assay is less than 3%; based on six standard replicates included
in the analysis [24].
Statistical analysis
Results are presented as mean values 6 standard deviation.
Differences in absolute levels of genomic methylation between the
colon biopsies were analyzed by the non-parametric Wilcoxon test
Table 2. Overview of primers and sequences for pyrosequencing assays.
Assay Forward Reverse Sequencing Sequence to analyse
LINE1 TTTTGAGTTAGGTGTGGGATATA AAAATCAAAAAATTCCCTTTC AGTTAGGTGTGGGATATAGT TTC/TGTGGTGC/TGTC/TG
Alu TTTTTTTTTAAAGGTTATG TCTATCCCTAAAATTAAAA TTTTTTTTTAAAGGTTATG TC/TG
doi:10.1371/journal.pone.0079044.t002
Table 3. Overview of cutting sites for restriction enzymes.
Ezyme Cutting sites Methylation effect
HpaII 59..C’CGG..39 blocked by mCpG
MspI 59..C’CGG..39 no effect
MunI 59..C’AATTG..39 no effect
EcoRI 59..G’AATTC..39 impaired cleavage
doi:10.1371/journal.pone.0079044.t003
Global Methylation Analyses
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Table 4. Absolute values for global DNA methylation estimated by 4 different methods.
Sample Condition/treatment LINE1 Alu LUMA HPLC
(data presented as mean % methylation ± SEM1, plus (%CV))
Colon biopsies Normal 71.6360.49* (2.15%) 53.0861.59** (9.49%) 34.7663.83 (34.82%) 3.2460.05* (4.53%)
Tumor 65.3861.39* (6.71%) 33.0263.62** (34.66%) 34.5062.61 (23.90%) 3.1360.06* (5.90%)
HeLa cells Untreated 50.2160.92** (3.16%) 5.2560.15 (4.83%) 52.7961.23 (4.05%) 2.0260.03** (2.06%)
5-AzaC treated 32.7760.21** (1.14%) 4.6660.38 (14.28%) 35.9864.22 (20.31%) 0.7060.04** (7.07%)
M059J cells Untreated 46.1360.45** (1.68%) 6.0960.82* (23.31%) 50.7561.00 (3.40%) 1.8960.01** (0.96%)
5-AzaC treated 32.2760.51** (2.76%) 1.9160.29* (26.24%) 40.8465.59 (23.70%) 0.9160.02** (4.26%)
1Data for measurements on DNA from colon biopsies are presented as mean % methylation for 10 paired samples of normal and tumor tissue (6 standard error of the
mean (SEM)). Data from analysis of DNA from the cells lines represent means of 3 technical replicates (6 SEM).
NB: The nature of the measurements is different for each of the assays so direct comparison of the methylation percentages between assays cannot be made.
*P,0.03 and **P#0.009; non-parametric Wilcoxon matched-pair test was used for comparison of normal vs. tumor tissue for colon biopsies, and unpaired
homoscedastic t-test was used to test for significance between 5-AzaC- treated and untreated cells (each cell line analyzed separately).
doi:10.1371/journal.pone.0079044.t004
Figure 1. Methylation levels cell lines before and after treatment with the demethylating agent 5-AzaC. As assessed by: A) the LINE1
assay (**P#0.001), B) the Alu assay (*P= 0.009), C) the LUMA assay (*P= 0.019), and D) the HPLC method (**P#0.001). Data are presented as the mean
% of methylation (n = 3) relative to the control (i.e. untreated cells). Error bars represent standard deviations.
doi:10.1371/journal.pone.0079044.g001
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for matched pairs, and for analysis of the cell-based data the
unpaired homoscedastic t-test was used. Correlations between
assays were assessed by linear regression and by Pearson’s
correlations. Bland-Altman plots were prepared to investigate
the agreement between pairs of assays. For these comparative
analyses, absolute values were converted to percentages relative to
the overall mean of each method (i.e. mean set at 100%), to
generate values of similar magnitude for all of the methods.
Statistical analysis was performed using SPSS v.19.0 and P,0.05
was considered statistically significant.
Results
An overview of the absolute values for measures of genomic
DNA methylation in the human cells and tissues obtained using
the 4 different techniques tested in this study is given in Table 4.
As expected, use of Alu, LINE1 and HPLC approaches showed
reduced levels of global methylation in both cell lines after 5-
azacytidine (5-AzaC) treatment (Table 4 and Figure 1). This
reduction was apparent with all 4 analytical approaches, but was
significant (P,0.05) only for LINE1, Alu, and HPLC approaches
for M059J cells and for LINE1, LUMA and HPLC for HeLa cells
(Table 1 and Figure 1). Estimates of global DNA methylation
obtained with HPLC, LINE1 and Alu were lower in colorectal
tumor tissue than in paired normal tissue, whereas there was no
detectable difference between tissue types when assayed by the
LUMA method (Table 4 and Figure 2). Because each assay
measures a different variable, it is difficult to compare absolute
values. Therefore, we normalized the values for controls (i.e. the
untreated cells and the normal colon tissue) to 100% for each assay
and recalculated the other values relative to these controls. The
results for the human cells are shown in Figure 1 and for the colon
biopsies in Figure 2. In both cases the HPLC and LINE-1 methods
showed the smallest variation between samples, while higher
variation was seen for Alu and LUMA methods (see Table 4 for
CV%).
Concerning technical replicates, the overall variation (expressed
as CV%) between the replicates of the treated cells was 2.5% for
LINE1, 18.5% for Alu, 13.8% for LUMA, and 2.2% for HPLC
based measurements. For the colon biopsies, the overall variation
(expressed as CV%) between the replicate measurements was
1.1% for LINE1, 6.7% for Alu, and 8.1% for LUMA. No
technical replicates were measured via HPLC due to low amount
of DNA available from the colon biopsies. However, the 5 mg/L
Figure 2. Methylation levels in tumor samples and in matched biopsies of normal colorectal mucosa. As assessed by: A) the LINE1 assay
(*P= 0.013), B) the Alu assay (**P= 0.005), C) the LUMA assay, and D) the HPLC method (*P#0.029). Data are presented as the mean % of methylation
(n = 10) relative to the control (i.e. normal colon biopsies). Error bars represent standard deviations.
doi:10.1371/journal.pone.0079044.g002
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dC and 0.5 mg/L 5mdC standards were measured five times
distributed throughout the HPLC run, and the CV between these
replicates was 0.5% and 2.6%, respectively. Earlier, we deter-
mined that the intra-individual sample variation of the HPLC
assay is less than 10% (i.e. CV%=3.5–7.5% between 6
measurements of the same sample, determined on different days,
with 3–4 replicates in each run; unpublished data).
Methylation estimates obtained using LINE1 for the cells and
colon biopsies corresponded best with data measured via the gold
standard HPLC approach (R2= 0.96, P,0.001; Figure 3A).
Although the correlation was weaker, the estimates obtained
using the Alu assay correlated significantly with the HPLC
estimates (R2 = 0.78, P,0.001; Figure 3B). In contrast, there was
no correlation between estimates of global DNA methylation
obtained by LUMA and those with HPLC (R2= 0.04).
Figure 4 shows the outcomes of Pearson correlation analyses for
all combinations of the 4 methylation assays. When considering all
data together, estimates for the LINE1 and Alu assays correlated
significantly with the HPLC method and with each other
(Figure 4A). Next we analyzed the data for each biological source
i.e. cells (HeLa and M059J) and colon biopsies separately. For the
cell lines, correlations between estimates of methylation by the
LINE1 and HPLC methods were positive, high and stable when
data for both cell lines were pooled and when each cell line was
considered separately (Figure 4B). Correlations between other pair
of methods were weaker overall and, in some cases, for example
Alu vs. LUMA were not significant (P.0.05) in any of the
comparisons. For the colon biopsies alone, the strongest (and
significant (P,0.05)) correlations were between Alu and LINE1
and Alu and HPLC. None of the other comparisons produced
significant correlations (Figure 4C).
In further investigation of the agreement between results from
each of the assays, Bland-Altman plots were prepared in which the
differences between assays (HPLC – second assay) were plotted
against the mean of the two measurements. Horizontal lines were
drawn at the mean difference, and at the limits of agreement,
which were defined as the mean difference plus or minus two times
the standard deviation of the differences. Overall there was little
bias (i.e. average difference) between estimates obtained using the
LINE1 assay versus HPLC (Figure 5A) and mean differences were
also low for Alu (Figure 5B) and LUMA (Figure 5C). However,
observed differences for individual samples between HPLC and
Alu or LUMA were much greater than for LINE1 compared to
HPLC. Bland-Altman plots can also reveal potential systematic
bias between assays and, for both LINE1 and Alu, there is
incidence of such systematic error, which appears to be
proportional to the absolute value for global DNA methylation.
Although in all cases the error was relatively small for LINE1,
LINE1 overestimated DNA methylation compared with HPLC
when methylation levels were relatively low, and underestimated
them compared to HPLC when methylation levels were higher
(Figure 5A). For Alu the opposite effect was observed: relatively
low levels of global DNA methylation were underestimated by the
Alu assay compared with HPLC, while samples with higher
methylation levels were overestimated by the Alu assay (Figure 5B).
As illustrated in Figure 5C, there was poor agreement between
estimates of methylation obtained by LUMA and those by HPLC.
With LUMA the error (difference from HPLC estimates) increased
with increasing global methylation levels, resulting in both over- or
underestimation depending on the specific sample.
Discussion
In mammals, changes in the pattern of DNA methylation across
the genome are observed during development and ageing and in
many pathological conditions. In addition, methylation patterns
are altered by dietary and other environmental exposures
throughout the life-course [25,26]. Assessment of global DNA
methylation is important since the extent of methylation can be
associated with functional consequences e.g. increased mutational
events and genomic instability or altered gene expression [13,27].
Although 5mC is the major modification of cytosine in mamma-
lian tissues, it has been shown recently that 5-hydroxymethylcy-
tosine also occurs in mammalian DNA and may be an
intermediate in the demethylation of 5mC [28]. In this study we
compared estimates of global DNA methylation using 3 widely
used surrogate assays (LINE1, Alu and LUMA) with each other
and with estimates obtained using the gold standard HPLC. The
latter is a robust, highly-reproducible methodology which provides
estimates of the density of 5-methyl–29-deoxycytidine (5mdC) in
total DNA and is often expressed relative to the total amount of 29-
Figure 3. Linear regressions showing the relationships be-
tween assays. Using both data from the cell lines (X 5-AzaC treated
or m untreated) and the colon tissues (N), significant linear associations
were observed A) between the HPLC method and the LINE1 assay and
B) HPLC method versus the Alu assay. Absolute values were used for
these analyses.
doi:10.1371/journal.pone.0079044.g003
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deoxycytidine (5mdC + dC). However, this assay requires a
relatively large amount of DNA (,1–5 mg) and the necessary
equipment is not always available. Widely used surrogate assays
include i) those which estimate the methylation of repetitive
elements in DNA e.g. LINE1 and Alu (quantitatively major
genomic domains for DNA methylation) or ii) those such as
LUMA which employ parallel digestion of DNA with isoschizo-
mers which recognize the same sequence but cut differentially
according to the methylation state of a cytosine residue in the
target sequence. All 3 of these techniques require relatively small
amounts of starting material (,100–500 ng DNA) and can be
used as medium throughput assays suitable for large numbers of
samples. In addition, all 3 of these surrogate assays cannot
distinguish between 5mC and 5hmC and quantify the sum of both
modifications [29,30]. In most cases, 5hmC is a minor component
of total methylated cytosine in DNA, but we have shown recently
that the 5hmC:5mC ratio in brain regions of mice can range from
0.15–0.30 [31]. However, the comparability of data obtained by
Figure 4. Correlation coefficients for the estimates of global DNA methylation as quantified by the various methods. A) Pearson
correlations for all data combined (n = 32), B) Pearson correlation coefficients when using the data from the cells (n = 6/cell type), and C) Pearson
correlations for the data from the colon biopsies (n = 20).
doi:10.1371/journal.pone.0079044.g004
Global Methylation Analyses
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the various surrogate assays and by HPLC is poorly understood
and failure to recognize this research gap may contribute to
misinterpretation of study outcomes and to apparent contradic-
tions between studies. Weisenberger et al. have studied compar-
isons between HPLC, LINE1 and Alu assays for assessment of
global DNA methylation using the MethylLight method [32].
Recently, Wu et al. reported a comparison of estimates of global
methylation using 3 assays for repetitive elements LINE1, Alu and
Sat2 (Satellite 2– located as tandem repeats in the pericentromic
and juxtacentromic heterochromatin of most chromosomes) using
MethyLight assays, for LUMA and for the 3H-methyl acceptance
assay in 4 different human blood cell types [33]. Our present study
extends consideration of this issue to human tissues, uses the fast,
easy but reliable, reproducible and more quantitative pyrose-
quencing approach instead of the MethyLight approach [34], and
includes the use of the gold standard HPLC assay for global DNA
methylation.
Detection of biologically-important differences in global
DNA methylation by each assay
Treatment with the demethylating agent 5-azacytidine (5-AzaC)
produced a similarly large (60–65%) reduction in global methyl-
ation of DNA from both HeLa and M059J cells as measured by
HPLC. All 3 surrogate assays detected lower methylation in 5-
AzaC-treated cells but the degree of hypomethylation detected
differed between assays and, in some cases, between cell lines
(Figure 1). With the exception of the Alu assay of 5-AzaC-treated
M059J cells, none of the surrogate assays revealed nearly as much
genomic hypomethylation as was observed using HPLC (Figure 1).
For 3 decades, it has been recognized that human tumors are
hypomethylated when compared with the corresponding normal
tissue [5,13,35] and, in the present study, using HPLC we
observed the expected lower methylation in colorectal tumor than
in matched normal colon (Figure 2). A similar inter-tissue
difference in global DNA methylation was detected by the LINE1
assay but the degree of hypomethylation in tumor appeared
relatively greater when assessed by Alu. In contrast, the LUMA
approach was unable to detect a difference in methylation between
normal and tumor tissue (Figure 2). These observations show that
some surrogate assays, notably LINE1, can detect biologically-
important differences in global DNA methylation when these
methylation changes are distributed widely across the genome.
Correlations between assays and comparison with the
gold standard HPLC
Weisenberger et al. previously showed strong correlations
between global methylation levels in LINE1, Alu and Sat2
measured via MethylLight-based methods versus HPLC method
[32]. For the comparisons made here, estimates of global
methylation obtained using LINE1 for pooled data from both
cell lines and from tumor and matched normal colon tissue
correlated most strongly (R2 = 0.96) with those obtained by HPLC
(Figure 3A). This was confirmed by the Bland-Altman analysis
(Fig. 5A). Importantly, the latter showed small potential biases in
LINE1-derived estimates which appeared to be slightly inflated
when absolute DNA methylation levels were relatively low and
somewhat underestimated at higher methylation levels (Figure 5A).
This apparent bias is most likely due to the relative importance of
LINE1 as a contributor to global methylation under different
circumstances. Across all cells tissues, Alu-derived estimates of
global methylation were quite strongly correlated (P,0.001) with
those from HPLC assays (Figure 3B), but Bland-Altman analysis
revealed much greater divergence between approaches in
estimates of DNA methylation (Figure 5B) than were apparent
for LINE1. In contrast, there was no overall correlation between
LUMA-derived global DNA estimates and those from HPLC
(Figure 3A), although a significant correlation was apparent when
data from the cells lines only were considered (Figure 3B).
Interestingly, Weisenberger et al. showed that the mean of specific
Alu and Sat2 measures combined led to improved correlations
with HPLC measurements, and advised that this composite
measure be used for MethyLight-based estimates of genomic 5mC
content [32]. When combining estimates of 5mC as detected by
our LINE1 assay with our Alu-based estimates, the observed
correlation of LINE1 with HPLC was not improved (R2= 0.89),
nor when taking the overall mean of all 3 assays versus HPLC
(R2= 0.86).
In studies of human blood cells, Wu et al. reported relatively
strong correlations (range 0.39–0.64) between estimates based on 3
repetitive elements (LINE1, Sat2 and Alu) [33], and we have
observed slightly higher correlations between LINE1 and Alu for
human cell lines (R= 0.68) and for human colon tissues (R= 0.76).
With the exception of HeLa cells (R= 0.86), our estimates of
global DNA methylation based on the LUMA approach did not
correlate significantly (P.0.05) with those for LINE1. This lack of
correlation was evident for the overall data, for M059J cells and
for colon tissues which supports the observation by Wu et al. of
low correlations (range 0.18–0.20) between LUMA and LINE1
[33]. The LUMA assay has the advantage that it can be used with
DNA from various species without extra optimization. In contrast,
the LINE1 and Alu assays are genome specific and separate assays
are necessary for different species. However, the LUMA assay
appears to be sensitive to a number of factors including quality of
the original DNA isolate (DNA fragmentation may skew results)
and the choice of isoschizomers used to cut DNA in a methylation-
sensitive manner. Although we performed some further optimiza-
tion to improve the assay including use of MunI in place of EcoRI
(Figure S1), additional optimization might be needed to improve
the robustness of the assay. In addition, when interpreting their
data, users of the LUMA assay should consider the distribution of
the target sequence for the assay (CCGG) across the genome and
the extent to which the internal cytosine in this sequence is
vulnerable to loss (or gain) of a methyl group in the particular
circumstances under study.
A major limitation of all measures of global DNA methylation,
including those investigated in this study, is that they do not
provide any information about where in the genome the
methylated cytosines are located. Loss or gain of methylation
from regions of heterochromatin is likely to have very different
biological consequences from similar changes in euchromatin. For
example, an exposure might result in increases in methylation at
some genomic locations which were counter-balanced by meth-
Figure 5. Bland-Altman plots representing the agreement of each of the surrogate assays. A) LINE1, B) Alu, and C) LUMA, with the gold
standard HPLC method. The differences between the two methods (HPLC – second assay) were plotted against the averages of the two
measurements, using both data from the cell lines (X 5-AzaC treated or m untreated) and the colon tissues (N). Horizontal lines were drawn at the
mean difference, and at the limits of agreement, which are defined as the mean difference plus or minus two times the standard deviation of the
differences. For these comparative analyses, absolute values were converted to percentages relative to the overall mean of each method (i.e. mean
set at 100%), in order to acquire values of similar magnitude for all of the methods.
doi:10.1371/journal.pone.0079044.g005
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ylation losses at other loci. In such a circumstance, use of a global
DNA assay could be misleading since it might indicate ‘‘no effect’’
whereas, in reality, there were changes in methylation across the
genome each of which might be biologically important but
resulted in no net change in global DNA methylation. For these
reasons, the results of assays which quantify methylation at
specific, and known, genomic loci are (usually) easier to interpret.
Conclusions
We did not find compelling evidence that any of the surrogate
assays for global DNA methylation investigated here (LINE1, Alu
and LUMA) could be substituted with confidence for the gold
standard measurement by HPLC although LINE1 seems likely to
be an acceptable surrogate in many cases. Results from a recent
study of global DNA methylation in murine cells and tissues
showed good correlation between LINE1 methylation and total 5-
methyl cytosine measured by liquid chromatography-mass spec-
trometry [36]. Note, however, that LINE1 contains a minority
(<17%) of all the CpGs in the human genome and the finding that
LINE1 methylation can change in some circumstances, e.g. in
primary prostate cancer, without a corresponding change in
overall genomic methyl cytosine content [15], is evidence that
LINE1 methylation changes should be interpreted with care.
Moreover, alternative approaches for the measurement of LINE1
methylation can be applied. For instance, high resolution melt
analysis [36], in addition to pyrosequencing, increases the
accessibility of this relatively inexpensive, and high throughput
surrogate assay for overall genomic DNA methylation. In
conclusion, our observations show that not all surrogate assays
studied here can accurately detect relatively large, biologically-
important differences in genomic DNA methylation, although, in
many circumstances the LINE1 assay seems to be an acceptable
surrogate for the gold standard method HPLC for measurement of
global genomic methylation.
Supporting Information
Figure S1 Validation curve for EcoRI incubated for 4 h in 1x
Tango buffer with 0, 25, 50, 75, and 100% methylated Lambda
DNA (A); Star activity was observed for EcoRI in 1x Tango buffer,
but not in 2x Tango buffer when incubated for 4 h with
methylated Lambda DNA (B); Validation curve for MunI
incubated with 0, 25, 50, 75, and 100% methylated Lambda
DNA for 4 h or 16 h (C); in 1x Tango buffer; and E) Patterns of
digested unmethylated and methylated Lambda DNA for 4 h in
1x Tango buffer with EcoRI or MunI, showing impaired cleavage
of EcoRI on methylated Lambda DNA (D).
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